The cDNA for one of the receptors for human tumor necrosis factor (TNF) has been isolated. This cDNA encodes a protein of 455 amino acids that is divided into an extracellular domain of 171 residues and a cytoplasmic domain of 221 residues. The extracellular domain has been engineered for expression in mammalian cells, and this recombinant derivative binds TNFa with high affinity and inhibits its cytotoxic activity in vitro. The TNF receptor exhibits similarity with a family of cell surface proteins that includes the nerve growth factor receptor, the human B-cell surface antigen CD40, and the rat T-cell surface antigen OX40. The TNF receptor contains four cysteine-rich subdomains in the extracellular portion. Mammalian cells transfected with the entire TNF receptor cDNA bind radiolabeled TNFa with an affinity of 2.5 x 10-' M. This binding can be competitively inhibited with unlabeled TNFa or lymphotoxin (TNFfi).
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Tumor necrosis factor a (TNFa) is a potent cytokine that elicits a broad spectrum of biological responses. TNFa causes the cytolysis or cytostasis of many tumor cell lines in vitro, induces the hemorrhagic necrosis of transplanted tumors in mice, enhances the phagocytosis and cytotoxicity of polymorphonuclear neutrophils, and modulates the expression of many proteins, including lipoprotein lipase, class I antigens of the major histocompatibility complex, and cytokines such as interleukin 1 and interleukin 6 (1-4). TNFa appears to be necessary for a normal immune response (5, 6) , but large quantities produce dramatic pathogenic effects (7) (8) (9) . TNFa has been termed "cachectin" since it is the predominant factor responsible for the wasting syndrome (cachexia) associated with neoplastic disease and parasitemia (1, 3) . TNF is also a major contributor to toxicity in Gramnegative sepsis, since antibodies against TNF can protect infected animals (7, 10) .
The many activities of TNFa are mediated by binding to a cell surface receptor. Radioligand binding studies have confirmed the presence of TNF receptors on a wide variety of cell types (11) (12) (13) (14) . Although these receptors are expressed in limited numbers (1000-10,000 per cell), they bind TNFa with high affinity (Ka = 109 M-1 at 40C). The TNF receptor has been characterized as a 55-to 80-kDa glycoprotein that binds both TNFa and the structurally related lymphotoxin (TNF, 8) .
Lymphotoxin has biological activities that are similar, if not identical, to those of TNFa, presumably because both are recognized by the same receptor (4) . Recently, several laboratories have detected heterogeneity in TNF receptor preparations (15, 16) and have proposed that at least two distinct cell surface molecules bind TNFa. In addition, both of these receptors appear to be released from cells in soluble form, as TNF-binding proteins of 30 kDa have been isolated from urine and serum (16) (17) (18) . This soluble extracellular domain retains the capacity to bind ligand with high affinity and therefore may be important in regulating concentrations of TNFa in vivo.
To further elaborate the structure of the TNF receptor, we have identified a cDNA for one of the receptor forms.* COS cells transfected with this cDNA bind TNFa with high affinity and this binding can be inhibited by unlabeled TNFa or lymphotoxin. A derivative of the TNF receptor, the extracellular domain, has also been expressed in COS cells. This results in the secretion ofa soluble recombinant receptor domain with characteristics similar to those of the TNFbinding protein.
MATERIALS AND METHODS
Reagents. Recombinant human TNFa and TNF.8 were generously supplied by Genentech as highly purified proteins derived from Escherichia coli. The specific activities of these preparations were approximately 107 units/mg, as measured in the murine L929 cell cytotoxicity assay. The synthetic oligonucleotides were prepared by Oswel DNA Service (University of Edinburgh).
Isolation of TNF Receptor cDNA Clones. Purification and partial amino acid sequence analysis of the TNF-binding protein have been described (16, 17) . The sequence of a peptide fragment (Glu-Met-Gly-Gln-Val-Glu-Ile-Ser-SerThr-Val-Asp-Arg-Asp-Thr-Val-Cys-Gly) was used to design a synthetic oligodeoxynucleotide probe (5'-AAG-GAG-ATG-GGC-CAG-GTT-GAG-ATC-TCT-TCT-ACT-GTT-GAC-AAT-GAC-ACT-GTG-TGT-GGC-3' ). The 57-mer DNA probe was labeled with 32P by T4 polynucleotide kinase (New England Biolabs) and used to screen a placental cDNA library in AgtlO (19, 20) . Approximately 800,000 phage were transferred to nitrocellulose filters and screened at reduced stringency (21) . Filters were incubated for 2 hr at 420C in 0.05 M sodium phosphate, pH 6.5/20% formamide/0.75 M sodium chloride/0.075 M sodium citrate/1% polyvinylpyrrolidone (Sigma)/1% Ficoll/1% bovine serum albumin (Sigma), and sonicated salmon sperm DNA (Sigma) at 50 ng/ml. The radiolabeled probe was then added to the filters (106 cpm/ml), which were hybridized for 16 hr. Filters were washed extensively in 0.06 M sodium chloride/0.006 M sodium citrate/1% SDS at 370C and positive clones were identified by autoradiography. Ten hybridizing clones were plaque-purified (19) and cDNA insert size was determined by polyacrylamide gel electrophoresis ofEcoRI-digested phage DNA. The inserts of two cDNA clones were sequenced by the dideoxy chaintermination technique (22 The TNF receptor derivative was also analyzed for inhibition of TNFa cytotoxic effects in vitro. The cytotoxicity assay was performed as described on the TNF-sensitive cell line WEHI 164 clone 13 (29) . Serial dilutions of culture supernatant from COS cells transfected with pTNFRecd or from mock-transfected controls were incubated with a constant amount of TNFa (1 ng/ml) for 1 hr at 370C before addition to the assay.
RESULTS
Isolation and Characterization of the TNF Receptor cDNA. Partial amino acid sequence of the TNF-binding protein (16, 17) was used to design a synthetic oligonucleotide probe. The radiolabeled probe was used to screen a human placental cDNA library in AgtlO, and 10 hybridizing phage were isolated. The nucleotide and deduced amino acid sequences of the longest cDNA clone are depicted in Fig. 1 . The third potential ATG initiation codon occurs at position 156 of the nucleotide sequence; the first two ATG codons are closely followed by termination codons, and the third ATG is preceded by the best translation initiation consensus nucleotides (30) . The Fig.  1 indeed encodes the TNF receptor, the cDNA was engineered for expression in mammalian cells. The cDNA contains an EcoRI site at position 1270 of Fig. 1 . The receptor coding sequence was isolated as a 1300-bp EcoRI fragment (containing all but the last 81 codons of the cytoplasmic domain) and inserted into the mammalian cell expression vector containing a cytomegalovirus promoter and simian virus 40 transcription termination sequences (26) . The resulting plasmid was transfected into COS cells, which were analyzed for TNF receptor expression after 3 days. As shown in Fig. 3A , the transfected cells specifically bound radioiodinated TNFa in a saturable and dose-dependent fashion. The
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732 MG TTG TGC CTA CCC CAG ATT GAG MT GTT MG GGC ACT GAG GAC TCA GGC ACC ACA GTG CTG TTG CCC CTG The extracellular domain of the TNF receptor is naturally shed from cells (16) (17) (18) . To produce a similar recombinant derivative, at stop codon preceding the transmembrane domain was engineered into the cDNA by PCR mutagenesis. The modified DNA was inserted into the expression plasmid and subsequently transfected into COS cells. After 3 days, the COS cell medium was tested for inhibition of TNFa binding to human U-937 cells. As shown in Fig. 4A , the transfected-cell medium inhibited -70% of the binding of TNFa. The recombinant TNF receptor derivative was next tested for inhibition of TNFa biological activity. A sensitive bioassay for TNFa is measurement of cytolysis of mouse WEHI 164 (clone 13) cells. The transfected-cell medium inhibited 60% of TNFa cytotoxicity on this cell line (Fig. 4B) . Medium from mock-transfected COS cells did not inhibit TNFa cytotoxicity or binding. These experiments demonstrate that the recombinant extracellular domain of the TNF receptor is capable of binding TNF and inhibiting its biological activity. DISCUSSION This paper describes the cDNA cloning of a human TNF receptor. The cDNA was isolated with a synthetic oligonucleotide probe based on partial amino acid sequence. The two peptide sequences determined for the purified TNF-binding protein correspond to sequences encoded in the cDNA. Confirmation that this cDNA encodes the TNF receptor was established by mammalian cell expression studies: this cDNA directs the expression of a cell surface protein that specifically binds TNFa with high affinity.
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Southern hybridization suggests that the cDNA is encoded by a single gene. Several other laboratories have provided strong evidence for at least two structurally distinct human TNF receptors (15, 16) . Consequently, other forms of the TNF receptor must differ significantly from that isolated here, since only single hybridization signals are observed in the Southern analysis (Fig. 2B) . Similarly, the ligands for this receptor, TNFa and lymphotoxin, share 35% amino acid similarity but their coding sequences do not cross-hybridize (32) .
The TNF receptor exhibits significant amino acid sequence homology to three other cell surface proteins: the low-affinity nerve growth factor receptor (28% similarity; ref. 33 (34) , and rat OX40 (35) . Common residues are boxed. OX40 contains only three subdomains and lacks the third. Residue numbers refer to the precursor form and begin with the initiating methionine. noglobulin]. We observed a single predominant signal in a Northern blot of human spleen and placenta mRNA, suggesting that one size of transcript produces this form of the TNF receptor. Consequently, the formation of the TNFbinding protein is most likely a result of proteolytic cleavage from the membrane-bound receptor. Presumably the extracellular domain is cleaved by proteolysis near the transmembrane junction, resulting in the release of a soluble receptor fragment.
By introducing a termination codon prior to the transmembrane domain, we have expressed a soluble form of the extracellular domain. This recombinant product mimics the natural TNF-binding protein in its sequence, amino acid composition, and ability to inhibit TNF biological activity (16, 17 (38) . Attempts to demonstrate the therapeutic potential of the recombinant soluble TNF receptor can now be instigated.
Note. After submission of this manuscript for review, two papers appeared (39, 40) 
